Ramos Camille, Guirguis Amira, Smeeton Nigel, Zaman Hadar, Felice Anna-Marie, Bancroft Stephanie, Gittins Rosalind, Hawksworth Gill, Corkery John Martin, Schifano Fabrizio
Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit, School of Life and Medical Sciences, University of Hertfordshire, Hatfield AL10 9AB, UK.
Swansea University Medical School, Institute of Life Sciences 2, Swansea University, Swansea SA2 8PP, UK.
Brain Sci. 2020 Mar 2;10(3):142. doi: 10.3390/brainsci10030142.
This survey aimed to explore knowledge and experience on novel psychoactive substances (NPS) of healthcare professionals (HCPs). The study also aimed to assess how HCPs would like to improve their knowledge of NPS. : Seventy paper questionnaires were disseminated in 2017 within continuing education events to pharmacists, nurses and general practitioners (GPs). Additionally, 127 online surveys were completed using the Qualtrics platform by other HCPs and mental health nurses in six United Kingdom (UK) independent mental health hospitals long-stay in-patient rehabilitation services. Two educational sessions involving pharmacists and GPs were also held in late 2017 and mid-2018. Knowledge of NPS by HCPs was evaluated prior to the start of the educational events. Evaluation forms were handed out post-sessions to garner feedback, especially on areas for improvement for future sessions. Statistical analysis of data was undertaken using SPSS (V.25). : Most HCPs reported only 'basic' to 'intermediate' NPS knowledge. Substance misuse service staff felt more informed, were more often consulted and had greater confidence regarding NPS compared to hospital and primary care professionals. A negative association was found between the age of the HCP and knowledge of NPS. Most participants expressed a need for regular training and updates as insufficient NPS-related information is currently received. : An improvement within the self-reported knowledge of HCPs on NPS is evident in comparison to previous studies. Continued education of HCPs on NPS is fundamental for the provision of improved harm reduction services, which can enhance overall care for NPS service users.
本次调查旨在探索医疗保健专业人员(HCPs)对新型精神活性物质(NPS)的知识和经验。该研究还旨在评估医疗保健专业人员希望如何提高他们对新型精神活性物质的了解。2017年,在继续教育活动中,向药剂师、护士和全科医生(GPs)发放了70份纸质问卷。此外,英国六家独立心理健康医院长期住院康复服务机构的其他医疗保健专业人员和心理健康护士通过Qualtrics平台完成了127份在线调查。2017年末和2018年年中还举办了两场涉及药剂师和全科医生的教育会议。在教育活动开始前,评估了医疗保健专业人员对新型精神活性物质的了解情况。会后发放了评估表以收集反馈,特别是关于未来会议改进方面的反馈。使用SPSS(V.25)对数据进行了统计分析。大多数医疗保健专业人员报告称,他们对新型精神活性物质的了解仅为“基础”到“中等”水平。与医院和初级保健专业人员相比,药物滥用服务人员感觉了解得更多,更常被咨询,并且对新型精神活性物质更有信心。发现医疗保健专业人员的年龄与对新型精神活性物质的了解之间存在负相关。大多数参与者表示需要定期培训和更新,因为目前收到的与新型精神活性物质相关的信息不足。与之前的研究相比,医疗保健专业人员自我报告的对新型精神活性物质的了解有了明显改善。对医疗保健专业人员进行新型精神活性物质方面的继续教育对于提供更好的减少伤害服务至关重要,这可以加强对新型精神活性物质服务使用者的整体护理。